Basal and postprandial levels of ghrelin and the nature of eating behaviour in patients with irritable bowel syndrome with constipation against the background of various degrees of obesity
Journal Title: Сучасна гастроентерологія - Year 2018, Vol 0, Issue 4
Abstract
Objective — to study the basal and postprandial serum levels of ghrelin, its association with types of eating behaviour and the appearance of constipation in patients with irritable bowel syndrome against the background of obesity. Materials and methods. The investigation of blood serum levels of ghrelin involved 10 healthy subjects with normal body weight and 50 patients. In compliance with the Rome criteria IV, the diagnosis of irritable bowel syndrome with constipation (IBSc) against the background of normal body mass was established in 18 patients (BMI — 19.7 ± 0.4 kg/m2), and in 32 subjects IBSc on the background of different stages of obesity (12 — I degree, BMI — 33.0 ± 0.4, 12 — II degrees, BMI — 37.9 ± 0.3 and 8 — III degrees, BMI — 42.6 ± 0.5 kg/m2). In all subjects, the ghrelin levels were determined in fasting blood and one hour after eating by using of the Ray Biotech Human Grelin kits. At the same time, in all surveyed subjects the type of eating behaviour (EB) was established with the use of the Dutch Eating Behaviour Questionnaire (DEBQ). Results. In has been established that in IBSc patients, the serum ghrelin levels in fasting blood was 2.1 times lower than in healthy subjects, and an hour after meals, the ghrelin level dropped in 2.7 times, while patients with IBSc only tended to decrease. In the patients with IBSc and obesity, the ghrelin levels in fasting blood were reduced in 1.8 times in patients with obesity of I degree, in 4.2 times at II degree and in 11.5 in case of III degree. In opposite to healthy subjects, the postprandial ghrelin levels in patients with IBSc and obesity, increased in 1.5; 2.1 and 2.7 times depending on the degree of obesity. The emotional type of EB was established in 56.25 % of patients with comorbid pathology. The probability of the development of constipation was the highest in patients with an emotional type of EB (OR — 24.43; p = 0.001) and lower in external EB (OR — 9.95; p = 0.04). Conclusions. The absence of the ghrelin levels’ reduction after meals in patients with irritable bowel syndrome against the obesity background was defined as a motivational factor for repeated episodes of eating. Its effects on the eating behaviour and stress (emotional and external to the type of eating behaviour) increased the constipations’ formation.
Authors and Affiliations
V. G. Mischuk, G. V. Grigoruk
Keywords
Related Articles
- EP ID EP417396
- DOI 10.30978/MG-2018-3-30
- Views 126
- Downloads 0
Pathogenetic role of visceral adipose tissue in the development of non-alcoholic fatty liver disease in patients with metabolic syndrome
Objective — to study the nature of changes in carbohydrate and lipid metabolism, depending on the distribution and activity of visceral adipose tissue (VAT), and the degree of liver steatosis in patients with nonalcoholi...
Masks of autoimmune hepatitis. Clinical observations
Autoimmune hepatitis is a diagnosis of exclusion. Based on literature data, a third of patients are diagnosed with other autoimmune diseases, which are combined with AIH, which aggravates the severity of the disease and...
The use of proton pump inhibitors in the general clinical practice: advantages and disadvantages
The article presents modern views on the use of proton pump inhibitors in clinical practice with account of the patients’ age, therapyduration and comorbidity. The analysis has been performed for the literature data and...
Novelties in the treatment of inflammatory bowel disease: outcome of the symposium 213 by the Falk Foundation
-
The results of multicenter study of efficacy of Helicobacter pylori eradication therapy, conducted according to the recommendations of Maastricht V Consensus Report
Objective — to study efficacy and safety of two weeks quadruple therapy with high doses of pantoprazole, bismuth subcitrate, clarithromycin, amoxicillin with concomitant adjuvant symbiotic therapy (Saccharomyces boulardi...